A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC). The goals of this study are to learn about: * The safety of the study treatment and if people tolerate it. * A safe dose level of I-DXd that can be used with other treatments. * Participant levels of prostate specific antigen (PSA) during treatment.

Trial Details

NCT ID
NCT06863272
Phase
PHASE1 / PHASE2
Sponsor
Merck Sharp & Dohme LLC
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Docetaxel
  • Ifinatamab Deruxtecan
  • Opevesostat
  • Abiraterone
  • Enzalutamide
  • Rescue Medication
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Orange, California, United States|33.78779,-117.85311
  • San Francisco, California, United States|37.77493,-122.41942
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Ann Arbor, Michigan, United States|42.27756,-83.74088

Key Eligibility Criteria

  • The main inclusion criteria include but are not limited to the following:
  • Has histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology
  • Has prostate cancer progression while on androgen deprivation therapy (ADT) (or post bilateral orchiectomy) within 6 months before Screening
  • Has current evidence of distant metastatic disease

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →